-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3839 Protein S Enhances the Phagocytosis of Phosphatidylserine-Positive Erythrocyte: Implications for the Erythrocytes Turnover

Program: Oral and Poster Abstracts
Session: 101. Red Cells and Erythropoiesis, Excluding Iron: Poster III
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Immune mechanism, Biological Processes
Monday, December 9, 2024, 6:00 PM-8:00 PM

Claire Auditeau1,2*, Aurelie Fricot-Monsinjon3,4*, Raphaël Gauthier5*, Zeynep Cacan6*, Céline Gounou7*, Alain Brisson8*, Laure Joseph, MD9,10*, Sandra Manceau, PhD3,11*, Mariem Khamari12*, Sophie Moog13,14*, Pierre Buffet, PhD3,15,16*, Laetitia Claer, MSc17*, Sandrine Laurance, PhD5*, Valentine Brousse, MD, PhD5,18*, Delphine Borgel, PhD, PharmD13,19*, Francois Saller, PhD13* and Camille Roussel, MD, PhD1,3,5*

1Service d'Hématologie Biologique, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France., Paris, France
2Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France, Le Kremlin Bicêtre, AL, France
3Laboratoire d'Excellence GR-Ex, Paris, France., Paris, France
4Université Paris Cité and Université des Antilles, Inserm, Biologie Tissulaire du Globule Rouge, Paris, France., PARIS, FRA
5Université Paris Cité and Université des Antilles, Inserm, Biologie Tissulaire du Globule Rouge, Paris, France., Paris, France
6Service d'Hématologie Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France., Paris, France
7UMR-CBMN, CNRS-Université de Bordeaux-IPB, 33600 Pessac, France., Pessac, France
8UMR-CBMN, CNRS-Université de Bordeaux-IPB, 33600 Pessac, France., Pessac, FRA
9Laboratory of Excellence GR-Ex, Paris, France
10Biotherapy Department, French National Sickle Cell Referral Center, Hopital Necker, AP-HP, Paris, France
11Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France., Paris, France
12Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France., Le Kremlin-Bicetre, FRA
13Hémostase, Inflammation, Thrombose (HITh), UMR-S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France., Le Kremlin Bicêtre, France
14Inovarion 251 Rue Saint Jacques 75005 Paris, Paris, France
15Université Paris Cité and Université des Antilles, Inserm, Biologie Tissulaire du Globule Rouge, Paris, France., Paris, FRA
16Université Paris Cité, Service de Maladies Infectieuses et Tropicales Hôpital Universitaire Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), IHU Imagine, Paris, France., Paris, France
17Université Paris Cité and Université des Antilles, INSERM, BIGR, F-75015 Paris, F97150 Pointe à Pitre, France, Paris, France
18Robert Debre Hospital, Paris, France
19Service d'Hématologie Biologique, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France., par, France

Introduction: Protein S (ProS) promotes the clearance of apoptotic cells (efferocytosis) exposing phosphatidylserine (PtdSer), by activating MerTK on macrophages (Anderson et al., Nat. Immunol. 2003). Klei et al (2020) showed that senescent erythrocytes transform into erythrocyte ghosts (eryghosts i.e erythrocytes lacking their hemoglobin content) before being engulfed by splenic red pulp macrophages. Eryghosts are observed in the splenic blood of healthy individuals but are virtually absent in the peripheral blood, while eryghosts with extensive PtdSer exposure were observed in the peripheral blood of patients with hemolytic anemia (Özpolat et al., 2022).

We hypothesized that ProS may play a role in erythrocytes turn-over enhancing the phagocytosis of PtSer-exposing eryghosts by RPM.

Materials and Methods: Erythrocytes were treated with ionomycin to induce PdSer exposure (iono-RBC), or transformed into eryghosts by osmotic shock, and characterized by imaging flow cytometry. PtdSer exposure was quantified by lactadherin staining. CFSE-labelled Iono-RBC or eryghosts were added to THP-1-derived macrophages in the presence or absence of ProS (50 or 100 nM) and of a MerTK inhibitor (UNC2025, 5µM). The percentage of fluorescent macrophages, thus having phagocytosed fluorescent iono-RBC or eryghosts, was quantified by flow cytometry. ProS effect on eryghosts phagocytosis was assessed using monocyte-derived macrophages (MDM) in a second model. PBMC were isolated from buffy coat and CD14-positive monocytes were selected. For MDM differentiation, purified cells were cultured with M-CSF for 5 days and IL-10 was added for 2 more days. Results are expressed as mean ± standard error of mean.

Results: A high proportion of iono-RBC and eryghosts exposed PdSer (76.4 ± 21.7%, n=41 and 53,8 ± 23,6% n=10, respectively). When incubated with iono-RBC, the percentage of fluorescent THP-1 macrophages significantly increased from 19.5 ± 0.6% to 26.8 ± 0.9% (p<0.05) and 31.9 ± 3.1% (p<0.01) with 50 and 100 nM of ProS respectively (n=3), and decreased from 33.4 ± 2.6% to 9.7 ± 1.0% (p<0.01) when the MerTK inhibitor was added (n=4). Imaging flow cytometry confirmed the ghost aspect in the brightfield, and eryghosts were positive for glycophorin A staining, confirming their erythroid nature. ProS enhanced the phagocytosis of eryghosts by THP-1 macrophages even more than that of iono-RBC, by an 11.8 ± 1.2-fold and a 1.9 ± 0.12- fold, respectively (n = 4, p<0.001). The prophagocytic effect of ProS on eryghosts was also confirmed using monocyte-derived macrophages. ProS significantly enhanced eryghosts phagocytosis from 11.2± 5.5% to 50.8 ± 9.3% (n=6, p<0.001).

Conclusion: As for nucleated cells, ProS enhances the phagocytosis of PdSer-exposing RBC by a MerTK-dependent mechanism. This discovery has implications in physiology, as ProS could be involved in erythrocyte turnover by enhancing the phagocytosis of eryghosts resulting from senescent erythrocyte hemolysis in the spleen. In hemolytic anemias such as sickle cell disease (SCD), circulating eryghosts have been described (Özpolat et al., 2022), probably due to hemolysis and functional hyposplenism. ProS levels are frequently moderately decreased in SCD patients, while ProS is detected on the surface of SCD patient's erythrocytes (Whelihan et al, 2016). ProS may be trapped on the surface of circulating eryghosts, worsening coagulation's ongoing activation. Hence, ProS may be an interesting target for future treatments in hemolytic anemias such as SCD.

Disclosures: Joseph: Vertex: Honoraria; GBT: Honoraria; Addmedica: Honoraria; Novartis: Honoraria. Brousse: Pfizer: Membership on an entity's Board of Directors or advisory committees; Vertex: Consultancy; NovoNordisk: Consultancy; Novartis: Other: adjudication comitee; Nuvamid: Consultancy. Borgel: CSL Behring: Research Funding. Saller: CSL Behring: Research Funding.

*signifies non-member of ASH